
3T Biosciences is an immunotherapy company focused on developing transformative, next-generation therapies for solid tumors and immune-mediated diseases. Their approach leverages the power of the immune system to target and destroy cancer cells, aiming to create safer, more effective, and potentially curative treatments for challenging cancers. The company is at the forefront of immunotherapy advancements.

3T Biosciences is an immunotherapy company focused on developing transformative, next-generation therapies for solid tumors and immune-mediated diseases. Their approach leverages the power of the immune system to target and destroy cancer cells, aiming to create safer, more effective, and potentially curative treatments for challenging cancers. The company is at the forefront of immunotherapy advancements.
Founded: 2017
Headquarters: South San Francisco / Menlo Park area
Focus: TCR-based immunotherapies and pHLA-targeting for solid tumors and immune-mediated diseases
Platform: 3T-TRACE (target libraries + machine learning)
Latest disclosed raise: Series A $40M (Aug 25, 2022)
Cancer immunotherapy; target discovery for T-cell receptor therapies and immune-mediated diseases.
2017
Biotechnology; Immunotherapy
$40,000,000
Participation from Lightspeed Venture Partners; company announced launch from stealth with this financing.
“Backed by institutional life-science investors including Westlake Village BioPartners and Lightspeed Venture Partners; Parker Institute for Cancer Immunotherapy listed as supporting investor.”